Os dados dos estudos SIRFLOX e FOXFIRE Global de 739 pacientes indicam:

  • A SG foi significativamente melhorada pela adição de SIRT com microesferas de resina SIR-Spheres® Y-90 direcionadas ao fígado à quimioterapia de primeira linha mFOLFOX6 (± bevacizumab) em pacientes com mCRC com tumor primário do lado direito (RSP) (mediana 22,0 vs 17,1 meses, com vs. sem SIRT, respectivamente; HR: 0,64 [IC 95%: 0,46-0,89] p = 0,008), o que se traduz em uma redução de 36% no risco de morte a qualquer momento, em comparação com pacientes que recebem quimioterapia isoladamente.
  • Não foi observada melhora significativa na sobrevida da adição da SIRT à quimioterapia de primeira linha com mFOLFOX6 para pacientes com tumores primários do lado esquerdo (LSP) (mediana 24,6 vs. 26,6 meses, com vs. sem SIRT, respectivamente; HR: 1,12 [95 % IC: 0,92-1,37] p = 0,264).

bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)

Gibbs P et al.  Clin Col Cancer 2018 Jun 12 ePub: doi: 10.1016/j.clcc.2018.06.001.

 


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×